Investment Rating - The report maintains a "Buy" rating for the company, with projected PE ratios of 42, 34, and 27 for the years 2025, 2026, and 2027 respectively [4] Core Insights - The company is expected to achieve a revenue of 2.584 billion RMB in 2025, representing a year-on-year growth of 25%. The net profit attributable to the parent company is projected to be 821 million RMB, up 22% year-on-year [2] - The company's core product, PFA, has been well-promoted, leading to synergistic growth. The company emphasizes cost control, focusing R&D and sales expenses on market promotion, clinical validation, and next-generation product development [2] - The product pipeline is continuously advancing, with new products in coronary and peripheral business expected to enter a harvest phase. The company is actively conducting various marketing activities to enhance product coverage and admission rates [3] Financial Projections - The projected net profits for the company from 2025 to 2027 are 821 million RMB, 1.009 billion RMB, and 1.290 billion RMB, reflecting growth rates of 22%, 23%, and 28% respectively [4] - Revenue growth rates are expected to be 25.08% in 2025, 22.52% in 2026, and 26.85% in 2027 [9] - The diluted earnings per share are forecasted to be 5.818 RMB in 2025, 7.157 RMB in 2026, and 9.147 RMB in 2027 [9]

Core Insights - The coronary access devices are essential consumables for percutaneous coronary intervention (PCI) surgeries, directly impacting surgical outcomes and complication control [1][6] - The industry is supported by a series of policies in China, including centralized procurement, innovation approvals, and grassroots medical construction, laying a solid foundation for high-quality development [6][10] - The number of coronary artery disease patients is steadily increasing globally and in China, with projections indicating 220 million patients worldwide and 27.879 million in China by 2024, highlighting significant growth potential for the industry [10] Industry Overview - Coronary access devices are specialized medical equipment and consumables used in PCI surgeries to establish and maintain access from the body surface to the coronary arteries, ensuring the smooth execution of angiography, balloon dilation, and stent implantation [1][6] - The devices are categorized into four main types: puncture devices, catheter systems, sheath sets, and auxiliary devices for pressure monitoring and vascular closure [3][4] Development Background - The development of coronary access devices is crucial for reducing cardiovascular disease mortality, enhancing medical accessibility, and promoting high-end device localization [6][8] - Recent policies in China aim to improve centralized procurement mechanisms, accelerate innovation device approvals, and standardize medical insurance payments, providing guidance for industry development [6][10] Market Analysis - The global coronary balloon dilatation catheter market is expanding, with functional balloons growing at a faster rate; the market size is expected to increase from $560 million in 2020 to $960 million in 2024, with a compound annual growth rate (CAGR) of 8.49% [12][14] - In China, the market is characterized by structural adjustments and rapid growth, with the general balloon market experiencing a temporary decline due to centralized procurement but expected to rebound, while functional balloons are projected to grow significantly, with a CAGR of 19.28% from 2024 to 2028 [14][16] Competitive Landscape - The competitive landscape of the coronary access device industry is tiered, with foreign companies dominating the high-end market while domestic leaders are accelerating their market penetration; by 2024, domestic companies are expected to capture 54.9% of the coronary balloon market [14][15] Future Trends - The industry is expected to evolve along three main directions: technological upgrades, deepening domestic substitution, and expansion of grassroots markets [16] - Innovations such as biodegradable materials and smart functions will drive high-end product iterations, while local companies will enhance core component localization through material and manufacturing process advancements [17][18] - The promotion of tiered diagnosis and treatment will reshape market demand, with a growing need for cost-effective and standardized products suitable for grassroots settings [18]

Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has received acceptance for its IPO on the Shenzhen Stock Exchange's ChiNext board, aiming to raise 1.7 billion RMB for its operations in the high-performance vascular interventional medical device sector [1]. Group 1: Company Overview - Boma Medical specializes in the research, production, and global sales of high-performance vascular interventional medical devices, positioning itself as a leading provider of complex vascular disease intervention solutions [1]. - The company has developed a comprehensive product matrix with over 50 product series, covering critical areas such as coronary intervention, peripheral intervention, neurointervention, blood dialysis pathways, and interventional accessories [1]. Group 2: Market Presence - Boma Medical's products are marketed in over 100 countries and regions, serving thousands of hospitals and medical centers globally, establishing a strong brand image in the vascular interventional medical device market [2]. - The company has maintained a stable and rapid growth trajectory in both domestic and international markets, with a projected compound annual growth rate (CAGR) of 48.98% in revenue from 2022 to 2024 [2]. Group 3: Financial Performance - In terms of market share, Boma Medical is projected to hold 9.6% of the coronary balloon dilation catheter market in China, ranking fourth overall and first among domestic brands, and 4.7% of the peripheral artery balloon dilation catheter market, ranking fifth [3]. - The company reported revenues of approximately 207 million RMB, 335 million RMB, 460 million RMB, and 303 million RMB for the years 2022, 2023, 2024, and the first half of 2025, respectively, with net profits showing a significant turnaround from a loss of 36 million RMB in 2022 to a profit of 35.6 million RMB in the first half of 2025 [3][4]. Group 4: Fundraising and Investment Plans - The funds raised from the IPO will be allocated to various projects, including the establishment of a global headquarters, production base upgrades, and research and development for interventional medical devices, with a total planned investment of approximately 1.814 billion RMB [3].

Core Insights - The article discusses the registration and quality management system assessments for medical devices in Guangdong Province, highlighting various companies and their products that have undergone evaluations and received approvals or required modifications [2][5]. Group 1: Company Registrations - Guangdong Weinuodun Medical Technology Co., Ltd. received approval for its medical ozone therapy device on November 3, 2025 [3]. - Guangdong Baisheng Medical Instrument Co., Ltd. passed the evaluation for high-frequency surgical equipment on November 3, 2025 [3]. - Shenzhen Kefu Biotechnology Co., Ltd. was approved for its continuous glucose monitoring system on November 4, 2025 [3]. - Guangzhou Wanfu Biological Technology Co., Ltd. received approval for its hepatitis B virus nucleic acid testing kit on November 10, 2025 [3]. - Shenzhen Karman Medical Equipment Co., Ltd. was approved for its intracranial pressure sensor and cerebrospinal fluid drainage set on November 12, 2025 [3]. Group 2: Quality Management System Assessments - The Guangdong Provincial Drug Administration is implementing a quality management system assessment for Class II medical devices, with results communicated to applicants via SMS or web queries since May 2022 [5]. - Companies such as Shenzhen Aibo Hechuang Medical Robot Co., Ltd. received approval for their vascular intervention surgery control system on November 27, 2025 [5]. - Guangdong Tiancheng Tianmei Medical Technology Co., Ltd. was approved for absorbable surgical sutures on November 19, 2025 [4].

Group 1 - The National Medical Products Administration (NMPA) announced the cancellation of medical device registration certificates for 20 products from 11 companies, following the Medical Device Supervision and Administration Regulations [1] - Among the canceled products are two from Shenzhen Maiketian Life Science Co., Ltd.: the coronary balloon dilation catheter (registration number: Guo Xie Zhu Zheng 20223030549) and the non-compliant coronary balloon dilation catheter (registration number: Guo Xie Zhu Zheng 20223030559) [1]